Brent A. Williams

Dr. Brent A. Williams


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2020 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
BWBrent A. Williams
Brent A. Williams
ACAlanna M. Chamberlain
Alanna M. Chamberlain
JBJames C. Blankenship
James C. Blankenship
EHElaine M. Hylek
Elaine M. Hylek
SVStephen Voyce
Stephen Voyce
The community and clinical burdens of atrial fibrillation (AF) have been growing in recent years, with projections estimating sustained increases in the immediate future.1-6 Multiple explanations have been posited for the AF increase, including an aging population, prolonged survival of individuals with cardiac conditions that predispose them to AF, and an increasing prevalence of AF risk factors, such as obesity and hypertension, in the at-risk populations.3,5,7-15 Moreover, some authors have perceived increased attention being directed to AF in recent years—commonly attributed to the introduction of new anticoagulants for stroke prevention—that may be increasing the propensity to document AF clinically, especially as a secondary diagnosis.14,16,17 Furthermore, prior studies have shown disproportionate increases in AF incidence by diagnostic setting (inpatient vs outpatient), although studies were discordant on the nature of these differences.18,19 Lastly, increasing AF may be partially attributed to more frequent utilization of electrocardiography (ECG) in both routine clinical environments and through implanted or wearable devices with continuous AF-detecting capabilities, thereby increasing the opportunity to uncover AF.3,7,9,10,14

1 December 2017 in The American Journal of Cardiology
Verified
Journal Article
Closed access
BWBrent A. Williams
Brent A. Williams
AHAshley M. Honushefsky
Ashley M. Honushefsky
PBPeter B. Berger
Peter B. Berger

11 May 2017 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
BWBrent A. Williams
Brent A. Williams
Fatigue is a common and distressing but poorly understood symptom among patients with heart failure (HF). This study sought to evaluate the prevalence, predictors, and prognostic value of clinically documented fatigue in newly diagnosed HF patients from the community. This retrospective cohort study consisted of 12,285 newly diagnosed HF patients receiving health care services through the Geisinger Health System, with passive data collection through electronic medical records (EMR). Incident HF, fatigue, and other study variables were derived from coded data within EMRs. A collection of 87 candidate predictors were evaluated to ascertain the strongest independent predictors of fatigue using logistic regression. Patients were followed for all-cause mortality for an average of 4.8 years. The associations between fatigue and 6-month, 12-month, and overall mortality were evaluated via Cox proportional hazards regression models. Clinically documented fatigue was found in 4827 (39%) newly diagnosed HF patients. Depression demonstrated the strongest association with fatigue. Fatigue was often part of a symptom cluster, as other HF symptoms including dyspnea, chest pain, edema, syncope, and palpitations were significant predictors of fatigue. Volume depletion, lower body mass index, and abnormal weight loss were also strong predictors of fatigue. Fatigue was not significantly associated with either 6-month (HR = 1.12, p = 0.16) or overall mortality (HR = 1.00, p = 0.89) in adjusted models. Fatigue is a commonly documented symptom among newly diagnosed HF patients, and its origins may lie in both psychologic and physiologic factors. Though fatigue did provide a prognostic signal in the short-term, this was largely explained by physiologic confounders. Proper therapeutic remediation of fatigue in HF relies on identifying underlying factors.

1 May 2018 in Atherosclerosis
Verified
Journal Article
Closed access
BWBrent A. Williams
Brent A. Williams
KCKevin M. Chagin
Kevin M. Chagin
LBLori D. Bash
Lori D. Bash
WBWilliam E. Boden
William E. Boden
SDSue Duval
Sue Duval
MBMarc P. Bonaca
Marc P. Bonaca

1 November 2013 in Heart & Lung
Verified
Journal Article
Closed access
BWBrent A. Williams
Brent A. Williams
MMMichael E. Merhige
Michael E. Merhige

14 December 2019 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
BWBrent A. Williams
Brent A. Williams
DGDaniela Geba
Daniela Geba
JCJeanine M. Cordova
Jeanine M. Cordova
SSSharash S. Shetty
Sharash S. Shetty
Background: Antidiabetic therapies have shown disparate effects on hospitalization for heart failure (HHF) in clinical trials. This study developed a prediction model for HHF in type 2 diabetes mellitus (T2DM) using real world data to identify patients at high risk for HHF.Hypothesis: Type 2 diabetics at high risk for HHF can be identified using information generated during usual clinical care.Methods: This electronic medical record‐ (EMR‐) based retrospective cohort study included patients with T2DM free of HF receiving healthcare through a single, large integrated healthcare system. The primary endpoint was HHF, defined as a hospital admission with HF as the primary diagnosis. Cox regression identified the strongest predictors of HHF from 80 candidate predictors derived from EMRs. High risk patients were defined according to the 90th percentile of estimated risk.Results: Among 54,452 T2DM patients followed on average 6.6 years, estimated HHF rates at 1, 3, and 5 years were 0.3%, 1.1%, and 2.0%. The final 9‐variable model included: age, coronary artery disease, blood urea nitrogen, atrial fibrillation, hemoglobin A1c, blood albumin, systolic blood pressure, chronic kidney disease, and smoking history (c = 0.782). High risk patients identified by the model had a >5% probability of HHF within 5 years.Conclusions: The proposed model for HHF among T2DM demonstrated strong predictive capacity and may help guide therapeutic decisions.